Mark Capone appointed to Sera Prognostics board, joins Compensation Committee

Sera Prognostics appointed Mark Capone as a Class II director effective July 1, 2026, and also named him to the Compensation Committee.Original SEC Filing: SERA PROGNOSTICS, INC. [ SERA ] - 8-K - Jun. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important i…

Sera Prognostics appointed Mark Capone as a Class II director effective July 1, 2026, and also named him to the Compensation Committee.

IndividualMark Capone

RoleClass II director; member of the Compensation Committee

Type of ChangeAppointed

Effective DateJuly 1, 2026

ReasonAppointment by Board upon recommendation of Nominating and Governance Committee

Replacement InfoNot disclosed

Background DetailsHealthcare executive with 40+ years; CEO of Precision Medicine Advisors since Mar 2020; former CEO of Myriad Genetics; director at Mesa Laboratories; extensive experience in diagnostics, biotech, devices, pharma; advanced degrees from MIT and Penn State

Board/Committee Role ChangesAppointed to Compensation Committee

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.